{"nctId":"NCT05093478","briefTitle":"The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population","startDateStruct":{"date":"2019-09-10","type":"ACTUAL"},"conditions":["Non-allergic Rhinitis"],"count":28,"armGroups":[{"label":"Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Intranasal capsaicin","Drug: topical lidocaine"]}],"interventions":[{"name":"Intranasal capsaicin","otherNames":[]},{"name":"topical lidocaine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic rhinitis\n\nExclusion Criteria:\n\n* Active smoker\n* Anatomic source of nasal symptoms\n* Chronic rhinosinusitis or other nasal infection\n* History of sinonasal malignancy\n* Pregnancy or lactation\n* Use of medication affecting nasal function (topical steroids, topical anticholinergics, oral antihistamines) in the previous 4 weeks\n* Use or abuse of nasal decongestants.\n* Positive skin prick test for allergic rhinitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.07","spread":"2.41"}]}]}]},{"type":"PRIMARY","title":"Runny Nose as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.89","spread":"2.04"}]}]}]},{"type":"PRIMARY","title":"Runny Nose as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"3.15"}]}]}]},{"type":"PRIMARY","title":"Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at Baseline","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.57","spread":"2.80"}]}]}]},{"type":"PRIMARY","title":"Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"2.13"}]}]}]},{"type":"PRIMARY","title":"Nasal Symptoms of Congestion as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.75","spread":"2.13"}]}]}]},{"type":"PRIMARY","title":"Nasal Itching as Measured by the Visual Analog Scale (VAS at Baseline","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.25","spread":"2.60"}]}]}]},{"type":"PRIMARY","title":"Nasal Itching as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":"1.95"}]}]}]},{"type":"PRIMARY","title":"Nasal Itching as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"1.84"}]}]}]},{"type":"PRIMARY","title":"Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at Baseline","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.03","spread":"2.47"}]}]}]},{"type":"PRIMARY","title":"Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.71","spread":"2.07"}]}]}]},{"type":"PRIMARY","title":"Nasal Sneezing as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment","description":"The Visual analog scale is scored from 0-10, with 0 being not a problem and 10 being unbearable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.29","spread":"2.91"}]}]}]},{"type":"PRIMARY","title":"Change in Maximum Optical Density Determined Via Optical Rhinometry","description":"Optical rhinometry provides continuous measurement of blood flow in nasal vessels (via optical density measurements), which serves as an indirect assessment of nasal congestion. A greater decrease in optical density (OD) from baseline indicates less nasal blood flow and decreased congestion relative to baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.18"}]}]}]},{"type":"PRIMARY","title":"Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at Baseline","description":"Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.92","spread":"7.03"}]}]}]},{"type":"PRIMARY","title":"Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 4 Weeks Post Treatment","description":"Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.57","spread":"6.69"}]}]}]},{"type":"PRIMARY","title":"Total Nasal Symptom Score as Measured by the Visual Analog Scale (VAS) at 12 Weeks Post Treatment","description":"Total Nasal Symptom score is measured as the sum of four symptom scores for runny nose, nasal symptoms of congestion, nasal itching and sneezing. Each symptom is scored from 0-10, with 0 being not a problem and 10 being unbearable. The Total nasal symptom score ranges from 0 - 40, the lower the score the better the outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"7.78"}]}]}]},{"type":"SECONDARY","title":"Change in Local Immunoglobulin E (IgE) Level","description":"The IgE levels will be obtained from the brush biopsy of the inferior turbinates. Change from baseline in local Immunoglobulin E (IgE) level after 12 weeks post treatment. Data reported is the 12 weeks post treatment value minus the baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"1.57"}]}]}]},{"type":"PRIMARY","title":"Maximum Optical Density Determined Via Optical Rhinometry","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":[]}}}